Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Drent, Esther, Poels, Renée, Mulders, Manon J., van de Donk, Niels W. C. J., Themeli, Maria, Lokhorst, Henk M., Mutis, Tuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976165/
https://www.ncbi.nlm.nih.gov/pubmed/29847570
http://dx.doi.org/10.1371/journal.pone.0197349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976165/
https://www.ncbi.nlm.nih.gov/pubmed/29847570
http://dx.doi.org/10.1371/journal.pone.0197349

Ejemplares similares